Aarti Pharmalabs credit ratios

Per cent unless marked ×
Tap a line for its trendLast 12Mto Sep 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
686686396264214
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
676676340170151
0.32×0.32×0.20×0.15×0.14×
0.32×0.32×0.17×0.10×0.10×
1.86×1.86×0.85×0.68×0.63×
1.39×1.83×0.73×0.44×0.44×
5.65×5.65×14.03×18.17×13.28×
23.3%24.4%16.6%13.1%12.1%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

AARTIPHARM₹927.65

Aarti Pharmalabs Ltd.

· Pharma & Health
₹ CrorePeersAARTIDRUGSADVENZYMESAGARWALEYEAKUMSALIVUSAPLLTDCORONAHCGMcap ₹8,410 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Total Debt214.0264.1396.4685.6685.6
Net Debt150.8169.6340.1676.0676.0
Total Debt/Equity0.140.150.200.320.32
Net Debt/Equity0.100.100.170.320.32
Total Debt/EBITDA0.630.680.851.861.86
Net Debt/EBITDA0.440.440.731.831.39
Interest Coverage (EBIT/Interest)13.2818.1714.035.655.65
Total Debt/Total Capital %12.0713.0716.6124.4023.32
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.